STENTYS Société anonyme announced audited earnings results for the year ended December 31, 2012. For the year, the company's revenues were EUR 2,530,700 compared to EUR 1,431,600 a year ago. Operational loss before share-based payment was EUR 9,950,800 compared to EUR 8,769,600 a year ago. Net loss was EUR 10,976,800 compared to EUR 9,503,300 a year ago. The sales performance recorded in 2012 continues to indicate substantial appeal for the STENTYS Self-Apposing stent amongst cardiologists in countries where it has been pre-marketed.

The company announced that following the FDA approval of its clinical trial in the United States, Professor Jacques Séguin decided to step down as a Director to focus on new early-stage projects and proposed to join the Scientific Advisory Board in order to continue advising STENTYS' clinical strategy. The Board of Directors has unanimously voted Michel Darnaud, as its new Chairman. A STENTYS Director since its IPO, Michel Darnaud is a seasoned medical technology professional with over 30 years of experience in the industry, including 20 years in management positions with companies such as Boston Scientific and the Sorin Group where he currently serves as President of the Cardiac Surgery Division. Additionally, the Board appointed the Fonds Stratégique d'Investissement (FSI) and its representative Maïlys Ferrère as a new Director.